Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2201 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

/PRNewswire/ -- Chengdu Origen Biotechnology Co., Ltd. ("Chengdu Origen") and Vanotech Ltd. ("Vanotech") announced today the first patient dosed in the...

Related Keywords

Chengdu ,Sichuan ,China ,Boston ,Massachusetts ,United States ,Avner Ingerman ,Origen Vanotech ,Vanotech Ltd ,Prnewswire Chengdu Origen Biotechnology Co Ltd ,Retina Research At Ophthalmic Consultants Of Boston ,Vitreoretinal Service ,Age Related Macular Degeneration ,Chief Medical Officer ,Retina Research ,Ophthalmic Consultants ,Chengdu Origen ,Private Securities Litigation Reform Act ,